Biologics and immunomodulators (IMM) are generally considered the most effective therapies for the treatment of ulcerative colitis and Crohn's disease. However, despite the efficacy of these therapies, many patients either have a primary lack of response or a secondary loss of response to these medications. Therapeutic drug monitoring (TDM) is a systematic approach to managing such patients. In this review, we summarize the latest data on TDM, including reactive and proactive TDM, in patients with inflammatory bowel disease on biologics and/or IMM.
Keywords: Crohn’s disease; Inflammatory bowel disease; Therapeutic drug monitoring; Ulcerative colitis.
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.